AVTX
Avalo Therapeutics, Inc.
$19.25
-0.71 (-3.56%)
At close · Jul 7
Market Cap
$1.01B
Shares
52,565,572
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$19.25
Open$20.40
Day$19.21–20.65
52W$4.61–24.27
Avg vol 30d1.9M
Short int7.4M · 14.1% float · 5.5d
Short vol71%
Last earningsMay 7, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 13
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+20%
above
Price vs 50-day avg
+18%
above
RSI (14)
61
neutral
MACD trend
Positive
52-week position
74%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+47%
trailing
6-month return
+15%
trailing
YTD return
+6%
this year
Relative strength
+8%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $16 › 200d $16 — 50d above 200d
Institutional flow
Accumulating
+19% holders QoQ · +34 funds added
Insider flow
Distributing
Net -$5.5M over 90 days · 100% sells
Short interest
Rising
14.10% of float · ▲ +16.2% MoM · 5.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
101 holders — near 2-yr high, broad support
Squeeze score
88
high risk · 0–100
Fundamentals
Revenue growth
+2312%
Y/Y
EPS growth
+72%
Y/Y
Free cash flow
$-51.6M
Balance sheet
$15.9M
net cash
Quant / Vol
risk profile
Volatility
93%
annualized · 1-yr
Max drawdown
−44%
past year
ATR
7.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 4, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+20%
Bullish
Price vs 50-day avg
+18%
Bullish
RSI (14)
61
Neutral
MACD trend
Positive
Bullish
52-week position
74%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $16 › 200d $16 — 50d above 200d
Institutional flow
Accumulating
+19% holders QoQ · +34 funds added
Insider flow
Distributing
Net -$5.5M over 90 days · 100% sells
Short interest
Rising
14.10% of float · ▲ +16.2% MoM · 5.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
101 holders — near 2-yr high, broad support
Price context
position in its 52-week range
52-wk low $5
Now $19 · 74%
52-wk high $24
vs 200-day avg +20%
vs 50-day avg +18%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AVTX
this stock
Avalo Therapeutics, Inc.
|
$1.01B | +6.0% | +2312.3% | — | 14.1% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.50B | +9.9% | +46.2% | 29.6 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.50B | -14.0% | +20.8% | 16.2 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AVTX | -0.2% | +47.0% | +15.5% | +4.2% | +6.0% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | -1.1% | +45.6% | +7.9% | +4.0% | -3.7% |